Management issues in treating COPD
==================================

COPD is a chronic disease and, like many other chronic diseases, there is no treatment to reverse the severity of the disease except for lung transplant. COPD is the fourth leading cause of death in the US and is expected to be the third by 2020. The prevalence of COPD is on the increase globally with an attendant increase in morbidity and mortality.

Despite the recent advances in understanding of the disease and its management, only a few therapies can have an impact on mortality in patients with stable COPD. These therapies include smoking cessation ([@b2-copd-3-575]), continuous oxygen therapy for hypoxemic patients ([@b45-copd-3-575]; [@b40-copd-3-575]), influenza vaccination ([@b43-copd-3-575]), and lung reduction surgery for selected patients ([@b29-copd-3-575]).

Pharmacotherapy for COPD has been used to alleviate symptoms, prevent exacerbations, and improve exercise capacity and quality of life. However, to date no inhaled medications have been shown to improve survival. The international guidelines developed by Global Initiative for Chronic Obstructive Lung Disease currently set the standard of care ([@b50-copd-3-575]) and long-acting bronchodilators are considered as the first-line maintenance therapy in patients with moderate to severe COPD.

The US Food and Drug Administration (FDA) recently issued a black box warning to long-acting beta agonists (LABAs) for asthma to alert healthcare professionals and patients that these medicines may increase the chance of severe asthma episodes and death ([@b31-copd-3-575]). Although information is not available for similar concerns applicable to patients with COPD, caution may be advised given the relatively high prevalence of reversible component in patients with very severe COPD and exclusion of such patients in most clinical trials.

A recent observational study of a cohort of 175,906 elderly COPD patients found that the use of inhaled corticosteroids (ICSs) was associated with a dose-dependent increase in hospitalization with pneumonia followed by death within 30 days ([@b28-copd-3-575]).

Combination therapy with a LABA with an ICS reduces COPD-related hospitalizations in patients with moderate to severe COPD and is the only pharmacotherapy that has been shown to alter the decline in lung function, which is a hallmark of the disease ([@b12-copd-3-575]). Further studies are needed to determine whether this combination might increase the number of adverse side effects given recently raised concerns with LABAs and ICSs.

Tiotropium bromide (Boehringer Ingelheim, Ingelheim, Germany) is a long-acting inhaled anticholinergic agent for the treatment of COPD that can improve lung function, reduce symptoms and COPD-related hospitalizations, and improve quality of life with once-daily dosing. The results of some studies have suggested that tiotropium is more effective than LABAs in reducing COPD-related hospitalizations and improving quality of life ([@b11-copd-3-575]; [@b46-copd-3-575]). Tiotropium was initially approved and marketed in several countries in Europe in June 2002 and then in the US in early 2004.

Two recently published studies have raised concerns for a possible increase in mortality and cardiovascular events with the use of inhaled anticholinergics. In a nested case-control study of a cohort of 32,120 COPD patients and 320,501 control participants, ipratropium bromide (Boehringer Ingelheim, Ingelheim, Germany) was associated with an increased risk for mortality, whereas ICSs appeared to reduce the risk for death ([@b38-copd-3-575]). In a 17-trial meta-analysis, the use of inhaled anticholinergics (ipratropium and tiotropium) was associated with an increased risk for a composite of myocardial infarction (MI), stroke and cardiovascular death ([@b55-copd-3-575]).

Although recent guidelines have advocated the use of inhaled anticholinergics for disease control ([@b50-copd-3-575]), there has been a growing concern in the clinical community that inhaled anticholinergics might increase the risk for cardiovascular events and mortality as describe above. This review examines the safety, tolerability and risk/benefit ratio of a long-acting anticholinergic agent, tiotropium bromide.

Overview of pharmacology of tiotropium and short- and long-acting bronchodilators
=================================================================================

Short- and long-acting bronchodilators
--------------------------------------

Short-acting beta-2 agonists act directly upon bronchial smooth muscle causing the airways to dilate for up to 6 hours. In turn, this improves 'smooth muscle dependent' outcome parameters such as symptoms and airway caliber (Sestini et al 2003).

The prime action of beta-adrenergic drugs is to stimulate adenyl cylase, the enzyme that catalyzes the formation of cyclic-3, 5-adenosine monophosphate from adenosine triphosphate.

Similar to short-acting agents, LABAs act directly upon beta-2 adrenoreceptors, causing smooth muscle to relax and airways to dilate. Both salmeterol (GlaxoSmithKline, Brentford, UK) and formoterol (Foradil^®^, Novartis Pharma AG, Basel, Switzerland) are relatively lipophilic, which may in part explain their prolonged duration of action.

Salmeterol interacts with both the active site and an exosite of the beta-2 adrenoreceptor, and the molecular basis of this interaction is termed the salmeterol hinge (charniere) theory ([@b47-copd-3-575]; [@b16-copd-3-575]). Formoterol is partially lipophilic and forms a membrane depot. Formoterol has a more rapid onset of action than salmeterol ([@b42-copd-3-575]).

The onset of action for both short- and long-acting beta-2 agonist is 5 to 15 min. Effects of short-acting agents usually last only 4 to 6 hours whereas those of LABAs last 12 hours.

Short- and long-acting anticholinergics
---------------------------------------

The characteristic airflow obstruction in COPD is multi-factorial in origin and in part due to potentially reversible high cholinergic tone ([@b35-copd-3-575]; [@b18-copd-3-575]). Moreover, vagally mediated mechanisms are also implicated in enhanced submucosal gland secretion in patients with COPD ([@b23-copd-3-575]).

Short-acting anticholinergics such as ipratropium (with a duration of action of 3 to 6 hours) offset high resting bronchomotor tone to relax smooth muscle with subsequent improvement in airway caliber ([@b39-copd-3-575]; [@b23-copd-3-575]; [@b52-copd-3-575]).

Three main subtypes (M1, M2 and M3) of muscarinic receptors exist. The activation of both M1 and M3 receptors results in bronchoconstriction whereas the M2 receptor is protective against such an effect.

In contrast to ipratropium, tiotropium dissociates rapidly from the M2 receptor (therefore minimizing the loss of any putative benefit) and dissociates only slowly from the M3 receptor ([@b24-copd-3-575]). This in turn causes a reduction in resting bronchomotor tone, smooth muscle to relax and airways to dilate for a greater length of time. The prolonged duration of action of tiotropium therefore facilitates once-daily administration with potential concordance benefits.

The peak onset of bronchodilation with tiotropium occurs persisting between 1 to 3 hours with improvements in FEV~1~ for over 24 hours ([@b3-copd-3-575]). In a pharmacodynamic study, it was discovered that 90% of the improvement in was achieved within 24 hours of first inhalation of FEV~1~ tiotropium, while ongoing improvements in forced vital capacity were expected beyond 1 week of regular treatment ([@b57-copd-3-575]).

Tolerability
------------

Inhaled LABAs are generally well tolerated although adverse effects such as fine tremor and palpitations are occasionally troublesome. These agents should be used in caution in patients with cardiovascular disease, at risk of developing prolongation of the QT interval and in whom concomitant drug administration may increase the risk of serious hypokalaemia ([@b53-copd-3-575]).

Tiotropium is generally well tolerated and poorly absorbed from the gastrointestinal tract, but as with all inhaled anti-cholinergic agents, care should be taken in patients with glaucoma and prostatic hyperplasia. In clinical trials comparing tiotropium with placebo, the frequency of dry mouth, constipation, and urinary tract infection appears to increase with patient age. Further details are described in the following section.

It is also important to point out that no tachyphylaxis to its bronchodilatory effect has been observed with tiotropium ([@b13-copd-3-575]), a phenomenon that is known to occur with LABAs ([@b25-copd-3-575]).

Safety and tolerability of tiotropium
=====================================

Comparison with placebo
-----------------------

Tiotropium was generally well tolerated in randomized clinical trials which ranged from 2 to 12 months ([@b15-copd-3-575]; [@b11-copd-3-575]; [@b44-copd-3-575]; [@b27-copd-3-575]; [@b59-copd-3-575]; [@b17-copd-3-575]; [@b22-copd-3-575]). In all studies, the completion rate was higher with tiotropium (77%--98%) than with placebo (71%--92%). The most commonly cited reason for withdrawal was worsening of COPD or adverse events. The completion rate in a recently published 4-year randomized controlled trial involving 5993 patients (UPLIFT, Understanding Potential Long-Term Impacts on Function with Tiotropium; [@b56-copd-3-575]) was significantly higher with tiotropium than with placebo (63% vs 55%, p \< 0.0001). The most common reason for withdrawal in the UPLIFT study was adverse events.

We conducted a pooled analysis to examine the incidence of serious adverse events (SAEs) and all-cause mortality using the same methods as in a recent meta-analysis by Singh et al. Ten randomized control trials reported incidence of SAEs ([@b13-copd-3-575], [@b15-copd-3-575], [@b14-copd-3-575]; [@b20-copd-3-575]; [@b44-copd-3-575]; [@b17-copd-3-575]; [@b22-copd-3-575]; [@b41-copd-3-575]; [@b56-copd-3-575]; [@b61-copd-3-575]) and 11 trials reported all-cause mortality ([@b13-copd-3-575], [@b15-copd-3-575], 2003[@b14-copd-3-575]; [@b44-copd-3-575]; [@b17-copd-3-575]; [@b48-copd-3-575]; [@b22-copd-3-575]; [@b41-copd-3-575]; [@b56-copd-3-575]; [@b61-copd-3-575]). There was no difference in all-cause mortality between the tiotropium and placebo recipients when all reported results were combined (odds ratio \[OR\] 0.94; 95% confidence interval \[CI\] 0.82--1.08). However, the incidence of SAEs was significantly lower in the tiotropium recipients (OR 0.88; 95% CI 0.81--0.96). ([Figure 1](#f1-copd-3-575){ref-type="fig"}) The most frequently reported SAEs were respiratory events such as COPD exacerbation or pneumonia ([@b14-copd-3-575]; [@b20-copd-3-575]; [@b44-copd-3-575]; [@b22-copd-3-575]; [@b56-copd-3-575]). The incidence of discontinuation due to adverse events was significantly lower with tiotropium than with placebo (21% vs 25%, p \< 0.0001) in the UPLIFT study ([@b56-copd-3-575]) as well as in a pooled analysis conducted by us (OR 0.79; 95% CI 0.71--0.88) ([Figure 2](#f2-copd-3-575){ref-type="fig"}).

The causes of death were consistent with what might be expected in the patient population. In a meta-analysis, pulmonary mortality was non-significantly lower with tiotropium than with placebo (OR 0.5; 95% CI 0.19--1.29) ([@b5-copd-3-575]). Cardiovascular (OR 1.17; 95% CI 0.54--2.51) and cancer mortality (OR 0.77; 95% CI 0.28--2.12) were similar in the tiotropium and placebo recipients.

There has been a growing concern in the clinical community that inhaled anticholinergics might increase the risk for cardiovascular adverse events. Although tiotropium was approved by FDA in 2004, the Pulmonary and Allergy Drugs Advisory Committee of the agency concerned about suggestions of increased cardiovascular risk when pivotal clinical trials were reviewed ([@b30-copd-3-575]). [@b5-copd-3-575] conducted a meta-analysis in 2006 in which the frequency of arrhythmia was significantly higher with tiotropium than with placebo when adjusted for statistical heterogeneity (OR 2.33; 95% CI 1.11--4.88).

In March 2008, The FDA issued a warning about a potential increased risk of stroke in patients using tiotropium ([@b32-copd-3-575]). Boehringer Ingelheim, the manufacturer of tiotropium, reported to the agency a preliminary estimate that the risk of stroke during 29 clinical trials was 8 patients per 1000 patients treated for 1 year with tiotropium and 6 patients per 1000 patients treated with placebo for the same amount of time. In these trials, which included approximately 13,500 patients with COPD, the estimated excess risk of any type of stroke caused by tiotropium was 2 patients for each 1000 patients using tiotropium for 1 year. The FDA cautioned practitioners that the findings were only preliminary and no regulatory action had been taken at that time.

After the FDA warning, two major studies were published concerning the possible association between inhaled anticholinergics and elevated risk for all-cause mortality and cardiovascular events. One study, which was a nested case-control study with a cohort of 32,120 case patients and 320,501 control participants, showed that ipratropium was associated with an increased risk for mortality in patients with COPD, whereas inhaled corticosteroids appeared to reduce the risk for death ([@b38-copd-3-575]). The use of ipratropium was associated with a higher risk of all-cause mortality (OR 1.11; 95% CI 1.08--1.15) and a 34 % increase (95% CI 22%--47%) in the risk for cardiovascular death, whereas ICSs and LABAs both reduced the risk for all-cause mortality by 20% and 8%. ICSs were also associated with a 20% decrease (95% CI 12%--28%) in the risk for cardiovascular death ([@b38-copd-3-575]).

The other study was a 17-trial meta-analysis, in which the use of inhaled anticholinergics (ipratropium and tiotropium), compared with control (placebo or comparator), was associated with an increased risk for a composite of MI, stroke and cardiovascular death ([@b55-copd-3-575]). The use of inhaled anticholinergics in patients with COPD was associated an increase risk for MI with a number needed to harm of 174 per year and an increased risk for cardiovascular death with a number needed to harm of 40 per year. The authors concluded that clinician should closely monitor patients with COPD who were receiving an inhaled anticholinergic agent.

Soon after the above two studies were published, the manufacturer reported the results of the UPLIFT study, which is a large 4-year, randomized, placebo-controlled, double-blind trial of tiotropium in patients with moderate to severe COPD conducted at 490 centers in 37 courtiers involving 5993 patients (Tashkin et al 2004). The UPLIFT study provided additional long-term safety data and additional insight into the risk of stroke or other safety findings of tiotropium.

Tiotropium showed a trend toward reduced mortality (14.9% vs 16.5%, hazard ratio \[HR\] 0.89; 95% CI 0.79--1.02). The incidence of adverse events (92.6% vs 92.3%) and the proportion of SAEs (51.6% vs 50.2%) were similar in the tiotropium and placebo group. Cardiovascular adverse events were significantly less with tiotropium (relative risk \[RR\] 0.84; 95% CI 0.73--0.98). The incidence of MI was also less with tiotropium (RR 0.71; 95% CI 0.52--0.99). There were 82 strokes among the 2987 patients (2.7%) taking tiotropium and 80 strokes among the 3006 patients (2.7%) taking placebo. The difference was not statistically significant.

We reanalyzed the meta-analysis conducted by [@b55-copd-3-575] incorporating the results of UPLIFT study to further investigate the possible association between tiotropium and increased risk of cardiovascular events. The association between inhaled anticholinergics (ipratropium and tiotropium) and increased risk for a composite of MI, stroke and cardiovascular death became no longer significant with the use of tiotropium ([Figures 3a](#f3a-copd-3-575){ref-type="fig"}, [b](#f3b-copd-3-575){ref-type="fig"}).

We also found the following errors in the meta-analysis by [@b55-copd-3-575]: 1) The number of the control group in the study by Chan et al was 305 instead of 350 ([@b17-copd-3-575]). 2) The incidence of serious cardiovascular events in the study by Wedzicha et al was 34 with tiotropium and 23 with placebo instead of 23 and 13 ([@b62-copd-3-575]). 3) The study by [@b26-copd-3-575] should have been excluded since [@b11-copd-3-575] reported combined results of the study by Donohue et al and another unpublished study ([@b4-copd-3-575]). Although these errors did not affect the results, they were corrected in our pooled analysis.

The difference in the cardiovascular events in the Singh's study was primarily derived from long-term studies (ie, duration of study \>6 months). We found evidence of possible publication bias when the long-term studies were analyzed with a funnel plot ([Figure 4](#f4-copd-3-575){ref-type="fig"}) and a statistical test (Horbold-Egger: bias = 0.722318 \[92.5% CI = 0.450252--0.994383\] p = 0.003). The difference in the cardiovascular events detected in the Singh's study could be due to publication bias. The FDA is currenlty reconsidering its recent warning that tiotropium might raise stroke risk as of October 10, 2008. The FDA said it would take several months for it to finish its review of the huge amount of data from the UPLIFT study.

The adverse event data indicated that anticholinergic effects were more frequent with tiotropium ([@b30-copd-3-575]; [@b5-copd-3-575]). Dry mouth was by far the most common with an incidence of 16% with tiotropium and 2.7% with placebo ([@b15-copd-3-575]) and more frequent in women and older patients ([@b30-copd-3-575]). The peak incidence has been reported to occur after 3 to 4 weeks of therapy, when steady-state concentrations are reached. Dry mouth was generally mild and resolved during treatment in most patients and less than 1% of the patients withdrew from the clinical studies as a result ([@b15-copd-3-575], 2003; [@b60-copd-3-575]). Other anticholinergic effects included constipation and urinary effects. The relative risk of urinary retention was significantly increased in a pooled analysis (RR 10.9; 95% CI 1.26--94.9) ([@b36-copd-3-575]). Upper respiratory tract infections were also more common with tiotropium than with placebo (41.1% vs 37.2%) ([@b30-copd-3-575]). The observation that dry mouth, constipation, and urinary tract infection occur more frequently with older age suggests that these adverse events represent systemic effects of the drug ([@b30-copd-3-575]). Tiotropium is associated with detectable plasma concentrations, particularly with chronic use. Other factors that can increase systemic exposure are impaired renal function, increasing age, concomitant cimetidine, and cytochrome P450 2D6 poor metabolizers ([@b30-copd-3-575]). It should be noted that patients with urinary problems and glaucoma were excluded in the most clinical trials; therefore, anticholinergic side effects may be more common in a real-world setting. The adverse effects of tiotropium are summarized in [Table 1](#t1-copd-3-575){ref-type="table"}.

Comparison with other bronchodilators
-------------------------------------

The tolerability of tiotropium in comparison with ipratropium ([@b60-copd-3-575]), salmeterol ([@b11-copd-3-575]; [@b10-copd-3-575]), formoterol ([@b58-copd-3-575]), or salmeterol/fluticasone (SFC) combination ([@b6-copd-3-575]; [@b62-copd-3-575]) was investigated in randomized clinical trials.

Fewer patients treated with tiotropium than with ipratropium (15.2% vs 21.2%) withdrew from the 1-year study ([@b60-copd-3-575]) but the difference was not statistically significant (p = 0.08). The withdrawal rates were also lower with tiotropium than with salmeterol. The difference was statistically significant in the 6-month trial (15.4% vs 18.8%; p \< 0.05) ([@b11-copd-3-575]) but not in the 3-month trial ([@b10-copd-3-575]) (8.8% vs 12.6%; p = 0.15). Similar proportions of tiotropium and formoterol recipients withdrew from the randomized crossover study ([@b58-copd-3-575]).

The withdrawal rate was similar between tiotropium and SFC in a 6-week trial ([@b6-copd-3-575]. However, in a 2-year randomized control trial, the withdrawal rate was significantly higher with tiotropium compared with SFC (HR 1.29; 95% CI 1.08--1.54; p = 0.005) ([@b62-copd-3-575]). In this study, more patients treated with tiotropium withdrew from the study because of COPD exacerbation, perceived lack of efficacy, or unwillingness to remain in the study.

There was no statistically significant difference in all-cause mortality comparing tiotropium with ipratropium ([@b60-copd-3-575]) or salmeterol ([@b11-copd-3-575]; [@b36-copd-3-575]). However, mortality was significantly higher with tiotropium than with SFC (6% vs 3%; p = 0.032) ([@b62-copd-3-575]). The leading causes of death, in order of prevalence, were cardiac, respiratory and neoplastic disorders. The incidence of cardiac death was non-significantly higher with tiotropium than with SFC (3% vs 1%; p = 0.09). The authors concluded that further studies powered on mortality would be required to confirm these findings since the all-cause mortality was not a primary outcome in the study ([@b62-copd-3-575]). It should be kept in mind that this study compared one drug (ie, tiotropium) with a combination therapy with a LABA and an ICS (ie, salmeterol plus fluticasone).

Dry mouth occurred more frequently with tiotropium than with ipratropium (12.1% vs 6.1%; p = 0.03) ([@b60-copd-3-575]) or with salmeterol (8.2% vs 1.7%; p \< 0.05) ([@b11-copd-3-575]). According to a recent meta-analysis ([@b5-copd-3-575]), other anticholinergic adverse events such as constipation, urinary retention and urinary tract infections occurred more frequently with tiotropium than with ipratropium or salmeterol. However, the differences were not statistically significant. The incidence of adverse cardiac events was similar between tiotropium and SFC (5% vs 3%, [@b62-copd-3-575]) or salmeterol ([@b11-copd-3-575]; [@b55-copd-3-575]). However, it is unlikely that these studies were sufficiently powered to detect a significant difference in the incidence of cardiac adverse events.

Patient satisfaction, adherence, and quality of life
====================================================

In clinical practice, frequent administration creates a problem with drug adherence. Adherence with inhaled medications are generally fair to poor with compliance rates of somewhere between 10% and 50% ([@b51-copd-3-575]; [@b8-copd-3-575]; [@b7-copd-3-575]; Kingsman et al 2007). Once-a-day administration with tiotropium is likely to improve compliance compared to multiple daily administration required with other inhaled medications. In a retrospective analysis including 5330 patients in the Netherlands, about 37% of new users of tiotropium continued treatment for 1 year whereas only 14% with ipratropium, 13% with LABA and 17% with LABA plus ICS remained on the treatment for the same duration ([@b9-copd-3-575]). A Canadian study also showed that patients taking tiotropium had significantly longer persistence at 12 months compared with other inhaled medications including ipratropium, ipratropium plus salbutamol, formoterol, formoterol plus budesonide, salmeterol, and salmeterol plus fluticasone (53% vs 7% to 30%; all p \< 0.0001) ([@b21-copd-3-575]).

There is a paucity of data on patient satisfaction with long-acting bronchodilators.

Risk benefit analysis of tiotropium
===================================

Tiotropium can improve lung function, reduce symptoms and exacerbations, and improve quality of life with once-daily dosing ([@b5-copd-3-575]). Tiotropium also showed a trend toward reduced mortality and induced long-term improvement in the UPLIFT study ([@b56-copd-3-575]).

Tiotropium is generally well tolerated with dry mouth being the main adverse effect.

Despite recently raised concerns about possible association between inhaled anticholinergics and elevated cardiovascular events, the risk/benefit ratio of tiotropium still appears favorable in symptomatic patients with moderate-to-severe COPD given the favorable safety profile demonstrated in the UPLIFT study. There were fewer cardiovascular events with tiotropium compared with placebo in the UPLIFT study. Our pooled analyses incorporating the UPLIFT study also confirmed the cardiac safety of tiotropium ([Figures 1](#f1-copd-3-575){ref-type="fig"}, [3](#f3a-copd-3-575){ref-type="fig"}). Respiratory events including COPD-related exacerbations and hospitalizations were also significantly less with tiotropium (RR 0.84; 95% CI 0.77--0.92) as shown in previous studies ([@b5-copd-3-575]; [@b46-copd-3-575]).

One caveat is that cardiac safety database is very limited in high-risk patients such as those with coronary artery disease, heart failure, cardiac arrhythmia, hypoxemia requiring daytime oxygen therapy, and a creatinine \>2.0 mg/dL since such patients were excluded from phase III clinical trials ([@b60-copd-3-575]; [@b11-copd-3-575]; [@b14-copd-3-575]; [@b44-copd-3-575]; [@b27-copd-3-575]; [@b56-copd-3-575]). Those patients may be at increased risk of drug-related cardiac events in a real-world setting.

Currently, it is largely clinician and patient preferences as to which inhaled long-acting bronchodilator to be used as the first-line maintenance therapy in symptomatic patients with moderate-to-severe COPD ([@b49-copd-3-575]; [@b50-copd-3-575]). For example, clinicians may prefer SFC over tiotropium given possible mortality benefit and/or better tolerability with SFC ([@b12-copd-3-575]; [@b62-copd-3-575]). Clinicians and patients may elect to use tiotropium over salmeterol if patients are experiencing frequent exacerbations or hospitalizations ([@b5-copd-3-575]). Third-party payers may elect tiotropium over salmeterol as a preferred drug in their formulary given more favorable cost-effectiveness ratio with tiotropium ([@b46-copd-3-575]).

Conclusions
===========

Tiotropium bromide is a long-acting inhaled anticholinergic agent and one of the first-line maintenance therapies in symptomatic patients with moderate-to-severe COPD. Tiotropium is generally well tolerated with dry mouth being the main adverse effect, which is generally not troublesome enough to discontinue the drug. Other adverse effects include constipation, tachycardia, blurred vision, urinary retention and increased intraocular pressure. Despite the recently raised concerns about an excess risk of cardiovascular adverse events with inhaled anticholinergic agents, the risk/benefit ratio of tiotropium appears still favorable given the favorable safety profile demonstrated in the UPLIFT study. However, caution should be advised in patients at high risk for cardiovascular disease given the paucity of data in such patients. The same is true for LABAs in patients with a reactive airway component and ICSs in patients at high risk for pneumonia.
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![Forest plot examining the incidence of discontinuation due to adverse events with tiotropium vs placebo including the UPLIFT study.\
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![Forest plot examining the incidence of composite cardiovascular events with anticholinergics vs control. Long-term trials (≥6 months) including UPLIFT study.\
**Abbreviations:** CI, confidence interval; RR, relative risk.](copd-3-575f3b){#f3b-copd-3-575}

![Funnel plot inspection on major adverse cardiovascular events in the long-term trials reveals significant asymmetry which suggests publication bias.\
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###### 

Adverse effects of tiotropium

  ------------------------------------------------------------
  Severe reactions
   Hypersensitivity reaction
   Angioedema
   Paradoxical bronchospasm
   Increased intraocular pressure/glaucoma
   Paralytic ileus
   Angina pectoris
   Stroke
  Common reactions (\>1%)
   Upper respiratory tract infection, pharyngitis, sinusitis
   Dry mouth, throat irritation
   Chest pain, tachycardia, palpitations
   Urinary tract infection, urinary hesitancy/retention
   Dyspepsia, vomiting, constipation, abdominal pain
   Edema
   Myalgia
   Epistaxis
   Rash
   Candidiasis
   Acute angle closure glaucoma, blurred vision, cataract
  ------------------------------------------------------------
